Unlock instant, AI-driven research and patent intelligence for your innovation.

Human anti-Abeta(1-32) amyloid antibody, purifying method and use thereof

An amyloid and human technology, applied in the direction of anti-animal/human immunoglobulin, antibody, pharmaceutical formula, etc., can solve the problems of reducing antibody concentration, lack of effective treatment for senile dementia, toxic and side effects, etc.

Inactive Publication Date: 2011-02-23
南京埃匹卡生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical trials proved that this treatment method caused very serious side effects and was stopped immediately (Dodel et al., Lancet Neurol2(4):215-20, 2003)
In addition, the treatment with humanized mouse anti-human Aβ antibody also produced a lot of toxic and side effects, because the protein sequence of the mouse antibody can cause the body's rejection immune response, especially the inflammatory rejection caused by long-term application , while reducing the concentration of antibodies in the body
[0009] In addition to the above findings, so far there is a lack of clinically available effective therapies for amyloid-related diseases, especially Alzheimer's disease
However, the incidence of senile dementia is increasing worldwide, so there is an urgent need for effective treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human anti-Abeta(1-32) amyloid antibody, purifying method and use thereof
  • Human anti-Abeta(1-32) amyloid antibody, purifying method and use thereof
  • Human anti-Abeta(1-32) amyloid antibody, purifying method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Anti-Aβ antibody was separated and purified by Aβ affinity chromatography column.

[0043] After passing 1g of immunoglobulin (IgG) through the Aβ1-40 affinity chromatography column, the Aβ antibody is eluted with an elution buffer (pH2.5). Most Aβ antibodies are obtained by eluting with an elution buffer with a pH of 2.5 . Chromatographic column: 3 mg of different Aβ polypeptide fragments Aβ 1-32 Combined with NHS-active separose 4 fast flow (Pharmacia, 5ml), the FPLC system of Pharmacia Company was used for purification at 4°C. with Aβ 1-40 The coated 96-well plate was used to complete the ELISA reaction. The result is as figure 1 shown.

Embodiment 2

[0045] Intravenous injection of purified human anti-Aβ 1-32 Antibody Therapy for Alzheimer's Disease Mouse Transgenic Animal Model (APPV717L)

[0046] In this example, human anti-Aβ 1-32 Antibody with or without anti-Aβ 1-32 Antibody IgG, dosed as human anti-Aβ 1-32 Antibody 100 micrograms / week / each, for two consecutive weeks. After one week of administration, changes in the contents of β-amyloid protein and β-amyloid protein antibody (Aβ antibody) in the cerebrospinal fluid and serum of the mouse brain can be observed. At the same time, the above indicators were measured before the administration and after the use of different doses of Aβ antibody, as a control. Its purpose is to reduce the concentration of β-amyloid in the cerebrospinal fluid or increase the concentration of Aβ in the blood, so as to reduce the formation of amyloid plaques in the brain.

[0047] The results showed that: with human anti-Aβ 1-32 After antibody treatment, the levels of total Aβ in the hip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new antibody as anti-A beta-1-32 starch protein antibody of human beings, which also provides a purifying method of antibody and application in the relative disease with original and secondary starch degenerating disease, especially for senile dementia and diagnosis.

Description

[0001] The present invention relates to a novel antibody, which is a human anti-Aβ 1-32 Amyloid antibodies. The present invention also relates to the purification method of the antibody, and the application of the antibody and its pharmaceutical composition in the treatment and diagnosis of amyloid-related diseases, including primary and secondary amyloidosis diseases, especially senile dementia application. Background technique [0002] Alzheimer's disease is a common progressive neurodegenerative disease. Patients initially present with partial amnesia, followed by restlessness, disorientation, aphasia, agnosia or apraxia (decreased cognitive ability), and dementia. Sometimes it manifests as euphoria and depression. The common age of onset extends from 40 to 90 years old, and there are more female patients than males. The number of people affected is estimated to be about 5% of the elderly population over the age of 65. Thus, Alzheimer's disease has become one of the ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/18A61K39/395A61P25/28A61K9/08
Inventor 杜燕生
Owner 南京埃匹卡生物科技有限公司